Ascentage Pharma Group International (AAPG)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Ascentage Pharma Group International, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Ascentage Pharma Group International (AAPG) has returned -9.03% so far this year and 8.75% over the past 12 months.

Based on dividend-adjusted daily data since Jan 24, 2025, AAPG's average daily return is +0.19%, while the average monthly return is +3.49%. At this rate, your investment would double in approximately 1.7 years.

Historically, 40% of months were positive and 60% were negative. The best month was Jun 2025 with a return of +61.4%, while the worst month was Dec 2025 at -19.3%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.

On a daily basis, AAPG closed higher 50% of trading days. The best single day was Mar 23, 2026 with a return of +16.8%, while the worst single day was Mar 20, 2026 at -13.3%.

Ascentage Pharma Group International has an annualized alpha of 51.88%, beta of 0.72, and R² of 0.04 versus S&P 500 Index. Calculated based on daily prices since January 27, 2025.

• This stock captured 91.17% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -93.34%) — a profile typical of hedging or uncorrelated assets.
• R² of 0.04 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

AAPG ranks 45 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Ascentage Pharma Group International (AAPG) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Ascentage Pharma Group International. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Ascentage Pharma Group International was 60.10%, occurring on Mar 20, 2026. The portfolio has not yet recovered.

The current Ascentage Pharma Group International drawdown is 50.17%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Ascentage Pharma Group International over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Ascentage Pharma Group International is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.